ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. has spent $885 million to buy three animal vaccine product lines in the U.S. from Boehringer Ingelheim, along with a manufacturing and R&D site. Meanwhile, Bayer is acquiring two parasite control products. The U.S. Federal Trade Commission required Boehringer to divest the businesses to complete a $13.5 billion swap of its consumer health business for Sanofi’s animal health subsidiary Merial on Jan 1. Last year, France’s Ceva Santé Animale bought nine Merial products to address European regulatory concerns.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter